|
[1]HARNOIS DM.Hepatitis C virus infection and the rising incidence of hepatocellular carcinoma[J].Mayo Clin Proc,2012,87(1):7-8.
|
|
[2]HWANG YH,CHOI JY,KIM S,et al.Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma[J].Hepatol Res,2004,29(2):113-121.
|
|
[3]WILHELM SM,CARTER C,TANG L,et al.BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis[J].Hepatol Res,2004,64(19):7099-7109.
|
|
[4]LIU L,CAO Y,CHEN C,et al.Sorafenib blocks the RAF/MEK/ERK pathway,inhibits tumor angiogenesis,and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5[J].Cancer Res,2006,66(24):11851-11858.
|
|
[5]MAO WF,SHAO MH,GAO PT,et al.The important roles of RET,VEGFR2 and the RAF/MEK/ERK pathway in cancer treatment with sorafenib[J].Acta Pharmacol Sin,2012,33(10):1311-1318.
|
|
[6]CHEN D,ZHAO P,LI SQ,et al.Prognostic impact of p ERK in advanced hepatocellular carcinoma patients treated with sorafenib[J].Eur J Surg Oncol,2013,39(9):974-980.
|
|
[7]FASOLO A,SESSA C.Targeting mT OR pathways in human malignancies[J].Curr Pharm Des,2012,18(19):2766-2777.
|
|
[8]GEDALY R,ANGULO P,HUNDLEY J,et al.PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mT OR pathways[J].Anticancer Res,2010,30(12):4951-4958.
|
|
[9]CHEN KF,CHEN HL,TAI WT,et al.Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells[J].J Pharmacol Exp Ther,2011,337(1):155-161.
|
|
[10]ZHANG CZ,WANG XD,WANG HW,et al.Sorafenib inhibits liver cancer growth by decreasing mT OR,AKT,and PI3K expression[J].J BUON,2015,20(1):218-222.
|
|
[11]GALUPPO R,RAMAIAH D,PONTE OM,et al.Molecular therapies in hepatocellular carcinoma:what can we target?[J].Dig Dis Sci,2014,59(8):1688-1697.
|
|
[12]LLOVET JM.Focal gains of VEGFA:candidate predictors of sorafenib response in hepatocellular carcinoma[J].Cancer Cell,2014,25(5):560-562..
|
|
[13]CHU JS,GE FJ,ZHANG B,et al.Expression and prognostic value of VEGFR-2,PDGFR-beta,and c-Met in advanced hepatocellular carcinoma[J].J Exp Clin Cancer Res,2013,32:16.
|
|
[14]MORGILLO F,MARTINELLI E,TROIANI T,et al.Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors[J].PLoSOne,2011,6(12):e28841.
|
|
[15]ERBER R,THURNHER A,KATSEN AD,et al.Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms[J].Faseb J,2004,18(2):338-340.
|
|
[16]HE G,KARIN M.NF-kappaB and STAT3-key players in liver inflammation and cancer[J].Cell Res,2011,21(1):159-168.
|
|
[17]ZHANG B,ZHONG DW,WANG QW,et al.Study on correlation of JAK/STAT signal pathway with progression and prognosis in hepatocellular carcinoma[J].Chin J Cell Immunol,2010,26(4):368-370,373.(in Chinese)张斌,钟德玝,王群伟,等.JAK/STAT信号通路与肝细胞性肝癌的肿瘤进展和预后的相关性研究[J].细胞与分子免疫学杂志,2010,26(4):368-370,373.
|
|
[18]WU WY,LI J,WU ZS,et al.STAT3 activation in monocytes accelerates liver cancer progression[J].BMC Cancer,2011,11(12):506.
|
|
[19]TAI WT,CHENG AL,SHIAU CW,et al.Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma[J].J Hepatol,2011,55(5):1041-1048.
|
|
[20]GU FM,LI QL,GAO Q,et al.Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3[J].World JGastroenterol,2011,17(34):3922-3932.
|
|
[21]KONG J,KONG F,GAO J,et al.YC-1 enhances the antitumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3(STAT3)in hepatocellular carcinoma[J].Mol Cancer,2014,13:7.
|
|
[22]BRACONI C,HENRY JC,KOGURE T,et al.The role of microR-NAs in human liver cancers[J].Semin Oncol,2011,38(6):752-763.
|
|
[23]LIN K,CIDAN WJ,CHANG ZH,et al.Clinical value of circulating microRNA in hepatic,biliary and pancreatic carcinomas[J].JClin Hepatol,2015,31(5):790-795.(in Chinese)林坤,次旦旺久,畅智慧,等.循环microRNAs在肝胆胰肿瘤发生发展中的作用[J].临床肝胆病杂志,2015,31(5):790-795.
|
|
[24]CHENG BX,FANG X,ZHU CL,et al.Altered expression levels of miRNAs in serum of patients with hepatocellular carcinoma in the treatment of sorafenib[J].China Med Herald,2014,11(9):41-44.(in Chinese)成炳祥,方煊,朱承良,等.索拉非尼对肝癌患者血清中肿瘤相关miRNAs的影响[J].中国医药导报,2014,11(9):41-44.
|
|
[25]HUANG S,HE X.The role of microRNAs in liver cancer progression[J].Br J Cancer,2011,104(2):235-240.
|
|
[26]BAI S,NASSER MW,WANG B,et al.MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib[J].J Biol Chem,2009,284(46):32015-32027.
|
|
[27]SALVI A,CONDE I,ABENI E,et al.Effects of miR-193a and sorafenib on hepatocellular carcinoma cells[J].Mol Cancer,2013,12:162.
|
|
[28]VAIRA V,RONCALLI M,CARNAGHI C,et al.MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma[J].Liver Int,2015,35(3):1077-1086.
|
|
[29]BLAGODATSKI A,POTERYAEV D,KATANAEV VL.Targeting the Wnt pathways for therapies[J].Mol Cell Ther,2014,2(1):28.
|
|
[30]CUI J,ZHOU X,LIU Y,et al.Wnt signaling in hepatocellular carcinoma:analysis of mutation and expression of beta-catenin,T-cell factor-4 and glycogen synthase kinase 3-beta genes[J].J Gastroenterol Hepatol,2003,18(3):280-287.
|
|
[31]WEI Y,SHEN N,WANG Z,et al.Sorafenib sensitizes hepatocellular carcinoma cell to cisplatin via suppression of Wnt/beta-catenin signaling[J].Mol Cell Biochem,2013,381(1-2):139-144.
|
|
[32]LACHENMAYER A,ALSINET C,SAVIC R,et al.Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib[J].Clin Cancer Res,2012,18(18):4997-5007.
|
|
[33]TANG Q,BU WH,WANG DD,et al.Advance research on interaction between autophagy and apoptosis and its influence in development of tumors[J].J Jilin Univ:Med Edit,2015,41(6):1303-1306.(in Chinese)唐琪,布文奂,王丹丹,等.自噬与凋亡的相互作用及其对肿瘤发展过程影响的研究进展[J].吉林大学学报:医学版,2015,41(6):1303-1306.
|
|
[34]FISCHER TD,WANG JH,VLADA A,et al.Role of autophagy in differential sensitivity of hepatocarcinoma cells to sorafenib[J].World J Hepatol,2014,6(10):752-758.
|
|
[35]SHIMIZU S,TAKEHARA T,HIKITA H,et al.Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma[J].Int J Cancer,2012,131(3):548-557.
|
|
[36]WANG K,LIN B.Inhibitor of apoptosis proteins(IAPs)as regulatory factors of hepatic apoptosis[J].Cell Signal,2013,25(10):1970-1980.
|
|
[37]ZHAO X,OGUNWOBI OO,LIU C.Survivin inhibition is critical for Bcl-2 inhibitor-induced apoptosis in hepatocellular carcinoma cells[J].PLoS One,2011,6(8):e21980.
|
|
[38]HIKITA H,TAKEHARA T,SHIMIZU S,et al.The Bcl-xL inhibitor,ABT-737,efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib[J].Hepatology,2010,52(4):1310-1321.
|
|
[39]ZHU H,CHEN XP,ZHANG WG,et al.Expression and significance of new inhibitor of apoptosis protein survivin in hepatocellular carcinoma[J].World J Gastroenterol,2005,11(25):3855-3859.
|
|
[40]LI XF,GONG RY,WANG M,et al.Sorafenib down-regulates c-IAP expression post-transcriptionally in hepatic carcinoma cells to suppress apoptosis[J].Biochem Biophys Res Commun,2012,418(3):531-536.
|
|
[41]LLOVET JM,RICCI S,MAZZAFERRO V,et al.Sorafenib in advanced hepatocellular carcinoma[J].N Engl J Med,2008,359(4):378-390.
|
|
[42]CHENG AL,KANG YK,CHEN Z,et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phaseⅢrandomised,double-blind,placebo-controlled trial[J].Lancet Oncol,2009,10(1):25-34.
|
DownLoad: